GENE ONLINE|News &
Opinion
Blog

2020-01-30| COVID-19

Update On 2019 Novel Coronavirus (2019-nCov): The Latest Progress In Vaccine Development And Treatment

by Sherry Hsiao
Share To

Efforts Around the World to Develop Vaccines

Anthony Fauci, director of the US National Institute of Alliance and Infectious Diseases (NIAID), claims that they are confident to conduct a clinical phase I trial of a vaccine against the 2019-nCov in three months or less.

Johnson & Johnson has begun research on the virus and has applied its technology platform for rapid and large-scale production of optimized vaccine candidates. Meanwhile, Moderna and Inovio Pharma have announced plans to work together to develop a vaccine.

The Chinese and Russian governments are also attempting to co-develop a vaccine, and Beijing has transferred the 2019-nCoV genome data to Moscow. “Russian and Chinese experts have started developing vaccines against coronavirus,” the Russian Consulate in Guangzhou said in a statement.

Despite these accelerated developments, Novartis CEO Vas Narasimhan has shared a different view. He warned that it would take at least a year to develop an effective vaccine, and what is needed now is epidemiological control to reduce the outbreak.

Antiviral Drug

Gilead Sciences is evaluating whether its experimental RNA polymerase inhibitor remdesivir, originally developed for the treatment of Ebola, can be used against the coronavirus. Besides, AbbVie stated that it had donated USD 2 million worth HIV drug Kaletra (lopinavir / ritonavir) as an “experimental option” at the request of Chinese health authorities.

Cell Therapy

Cell therapy-related companies are not shying away from this fight either. Sorrento Therapeutics has announced a collaboration with Celularity for clinical development and manufacturing. The goal is to extend the therapeutic use of Celularity’s CYNK-001 (an allogeneic, off-the-shelf, placental-derived Natural Killer cell therapy) to treat and prevent coronavirus infections.

Related Article: Understanding the Scientific Challenges in Combating the New Coronavirus


References
  1. https://www.marketwatch.com/story/coronavirus-update-vaccine-expected-in-phase-1-trial-within-months-who-to-reconvene-on-thursday-2020-01-29
  2. https://www.jnj.com/latest-news/what-you-need-to-know-about-coronavirus-and-a-potential-johnson-johnson-vaccine
  3. https://www.nytimes.com/2020/01/28/health/coronavirus-vaccine.html
  4. https://www.washingtonpost.com/world/asia_pacific/coronavirus-china-live-updates/2020/01/29/d49b9194-423b-11ea-b503-2b077c436617_story.html
  5. https://www.sciencemag.org/news/2020/01/can-anti-hiv-combination-or-other-existing-drugs-outwit-new-coronavirus
  6. https://www.covaxx.com/press-release-jul15-1

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
2024-03-01
M&A
Gilead Sciences Acquires CymaBay for $4.3 billion, Heralding a New Era in PBC Treatment
2024-02-15
LATEST
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
2024-04-12
Oncology’s New Drugs on the Horizon (I): Cancer Immunotherapy and Targeted Therapy
2024-04-12
Vertex Pharmaceuticals Makes $4.9 Billion Bet on Kidney Disease Treatment through Alpine Immune Acquisition
2024-04-11
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
2024-04-10
Pharmacogenomics (PGx) Shaping the Dynamic APAC Regions
2024-04-10
Connecting Biotech Ecosystems: Success of Los Angeles Event Sets Stage for APAC-US Collaboration
2024-04-10
Innovating Prostate Cancer Care: SYNC-T, Proteogenomics, and Culturally Tailored Education at AACR 2024
2024-04-10
EVENT
Scroll to Top